Innovative Medicine — Realized gain (loss)
Business Segments · Realized gain (loss)Johnson & Johnson Innovative Medicine — Realized gain (loss) remained flat by 0.0% to $25.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 125.0%, from -$100.00M to $25.00M. Over 2 years (FY 2022 to FY 2024), Innovative Medicine — Realized gain (loss) shows an upward trend with a -62.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful asset liquidation or investment performance, while a decrease indicates losses on disposals.
Detailed definition
This metric tracks the net gains or losses recognized upon the sale or disposal of assets, investments, or financial ins...
Peer comparison
Common in large diversified healthcare firms that manage internal investment portfolios.
jnj_segment_innovative_medicine_realized_gain_lossHistorical Data
| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | -$700.00M | -$400.00M | $100.00M |
| YoY Change | — | +42.9% | +125.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — realized gain (loss)?
- Johnson & Johnson (JNJ) reported innovative medicine — realized gain (loss) of $25.00M in Q4 2024.
- How has Johnson & Johnson's innovative medicine — realized gain (loss) changed year-over-year?
- Johnson & Johnson's innovative medicine — realized gain (loss) increased by 125.0% year-over-year, from -$100.00M to $25.00M.
- What is the long-term trend for Johnson & Johnson's innovative medicine — realized gain (loss)?
- Over 2 years (2022 to 2024), Johnson & Johnson's innovative medicine — realized gain (loss) has grown at a -62.2% compound annual growth rate (CAGR), from -$700.00M to $100.00M.
- What does innovative medicine — realized gain (loss) mean?
- The net profit or loss from selling assets or investments held by the Innovative Medicine segment.